Published in J Can Acad Child Adolesc Psychiatry on May 01, 2010
Barriers and facilitators to implementation of a metabolic monitoring protocol in hospital and community settings for second-generation antipsychotic-treated youth. J Can Acad Child Adolesc Psychiatry (2011) 1.40
Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry (2011) 1.27
Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatr Child Health (2011) 0.91
Therapeutic approaches for shankopathies. Dev Neurobiol (2013) 0.90
A Qualitative Study of Antipsychotic Medication Experiences of Youth. J Can Acad Child Adolesc Psychiatry (2015) 0.86
Review of the pharmacotherapy of irritability of autism. J Can Acad Child Adolesc Psychiatry (2012) 0.86
Prescribing trends of antipsychotics in youth receiving income assistance: results from a retrospective population database study. BMC Psychiatry (2013) 0.85
System struggles and substitutes: A qualitative study of general practitioner and psychiatrist experiences of prescribing antipsychotics to children and adolescents. Clin Child Psychol Psychiatry (2015) 0.83
Rising antipsychotic prescriptions for children and youth: cross-sectoral solutions for a multimodal problem. CMAJ (2014) 0.82
Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods. Child Adolesc Psychiatry Ment Health (2013) 0.80
The need for a proper definition of a "treatment refractoriness" in tourette syndrome. Front Integr Neurosci (2011) 0.78
[Not Available]. Paediatr Child Health (2012) 0.76
Some side effects and effcts on physical activity of second-generation antipsychotics: A study in children and adolescents. Adv Biomed Res (2014) 0.75
SENTIA: a systematic online monitoring registry for children and adolescents treated with antipsychotics. Springerplus (2014) 0.75
Health Information Preference among Youth and Caregivers related to Second-Generation Antipsychotic Treatment. J Can Acad Child Adolesc Psychiatry (2012) 0.75
Atypical antipsychotics for psychosis in adolescents. Paediatr Child Health (2014) 0.75
Combined stimulant and antipsychotic treatment in adolescents with attention-deficit/hyperactivity disorder: a cross-sectional observational structural MRI study. Eur Child Adolesc Psychiatry (2014) 0.75
CDC growth charts: United States. Adv Data (2000) 38.32
Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med (1998) 15.09
Obesity and the metabolic syndrome in children and adolescents. N Engl J Med (2004) 13.99
Risperidone in children with autism and serious behavioral problems. N Engl J Med (2002) 9.35
Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care (2004) 9.16
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA (2009) 6.91
Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA (2003) 6.60
Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs (2005) 5.84
Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA (2003) 4.88
The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes (2007) 4.84
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry (2004) 3.59
National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry (2006) 3.38
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry (2008) 3.30
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics (2004) 3.07
Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry (2005) 2.94
A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry (2009) 2.69
Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med (2008) 2.41
Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. Am J Ment Retard (2001) 2.23
Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics (2009) 2.13
Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry (2007) 2.11
Case study: risperidone-induced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry (1997) 2.01
Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry (2006) 2.00
Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med (1998) 1.95
A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry (2008) 1.89
Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry (2002) 1.89
Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics (2002) 1.87
The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res (2004) 1.85
A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry (2006) 1.78
Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol (2004) 1.76
Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry (2002) 1.75
Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. J Clin Psychopharmacol (2008) 1.70
Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry (2009) 1.61
A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry (2001) 1.61
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry (2002) 1.60
Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. J Clin Psychiatry (2005) 1.60
Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry (2009) 1.55
Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr (2006) 1.55
A placebo-controlled trial of risperidone in Tourette syndrome. Neurology (2003) 1.52
Who are the new users of antipsychotic medications? Psychiatr Serv (2008) 1.50
Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists. Australas Psychiatry (2008) 1.47
Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry (2000) 1.36
The genetics of childhood-onset schizophrenia: when madness strikes the prepubescent. Curr Psychiatry Rep (2009) 1.33
A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry (2002) 1.32
Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry (2003) 1.32
Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care (2009) 1.30
Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry (2009) 1.28
Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol (2009) 1.27
Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol (2005) 1.24
Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl) (2006) 1.19
Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry (2004) 1.19
Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry (2006) 1.18
Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry (2004) 1.16
Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol (2000) 1.16
Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation. J Am Acad Child Adolesc Psychiatry (2005) 1.16
Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry (2009) 1.15
Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry (2002) 1.14
A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord (2009) 1.14
Pancreatitis associated with quetiapine use. J Clin Psychopharmacol (2004) 1.13
Use of antipsychotic medications in Australia between July 1995 and December 2001. Aust N Z J Psychiatry (2003) 1.11
Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry (2006) 1.10
Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry (2008) 1.10
A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry (2006) 1.08
Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol (2006) 1.06
Prescription of antipsychotic drugs by office-based physicians in the United States, 1989-1997. Psychiatr Serv (2002) 1.05
Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. Drug Saf (2007) 1.04
Proposed definitions of bipolar I disorder episodes and daily rapid cycling phenomena in preschoolers, school-aged children, adolescents, and adults. J Child Adolesc Psychopharmacol (2007) 1.02
Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs (2002) 1.01
Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord (2007) 1.01
Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation. Schizophr Bull (2008) 1.00
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J Clin Psychiatry (2001) 1.00
Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs (2004) 1.00
A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic. J Child Adolesc Psychopharmacol (2009) 1.00
Effects of development on olanzapine-associated adverse events. J Am Acad Child Adolesc Psychiatry (2002) 0.99
Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics. J Child Adolesc Psychopharmacol (2007) 0.99
Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol (2004) 0.99
Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol (2009) 0.98
Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol (2001) 0.98
Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry (2004) 0.97
Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry (2007) 0.97
Possible hypothyroidism associated with quetiapine. Ann Pharmacother (2000) 0.95
Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry (2007) 0.94
The metabolic syndrome and schizophrenia: a review. Int Rev Psychiatry (2005) 0.94
Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications. Can J Psychiatry (2009) 0.93
Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol (1999) 0.93
Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry (2007) 0.92
Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry (2004) 0.92
Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry (2009) 0.90
Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol (2002) 0.90
Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol (2000) 0.90
A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry (2004) 0.89
Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients aged under 18 years. Can J Psychiatry (2007) 0.89
The second-generation 'atypical' antipsychotics: similar improved efficacy but different neuroendocrine side effects. Psychoneuroendocrinology (2003) 0.89
Waist circumference as a screening tool for the identification of adolescents with the metabolic syndrome phenotype. Int J Pediatr Obes (2009) 0.89
A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol (2006) 0.88
Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. J Child Adolesc Psychopharmacol (2001) 0.87
Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study. Eur Child Adolesc Psychiatry (2002) 0.87
Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry (2009) 0.86
Cognitive effects of risperidone in children with autism and irritable behavior. J Child Adolesc Psychopharmacol (2008) 0.86
Multiple antipsychotic use associated with metabolic and cardiovascular adverse events in children and adolescents. Evid Based Ment Health (2009) 0.86
Barriers and facilitators to implementation of a metabolic monitoring protocol in hospital and community settings for second-generation antipsychotic-treated youth. J Can Acad Child Adolesc Psychiatry (2011) 1.40
Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry (2011) 1.27
Focus on aripiprazole: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry (2009) 1.21
A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic. J Child Adolesc Psychopharmacol (2009) 1.00
Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications. Can J Psychiatry (2009) 0.93
Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatr Child Health (2011) 0.91
Priority-setting for children's mental health: clinical usefulness and validity of the priority criteria score. J Can Acad Child Adolesc Psychiatry (2007) 0.89
Waist circumference is a sensitive screening tool for assessment of metabolic syndrome risk in children treated with second-generation antipsychotics. Can J Psychiatry (2012) 0.88
A population-based study of antipsychotic prescription trends in children and adolescents in British Columbia, from 1996 to 2011. Can J Psychiatry (2013) 0.87
Prevalence and patterns of antipsychotic use in youth at the time of admission and discharge from an inpatient psychiatric facility. J Clin Psychopharmacol (2014) 0.86
The centre for healthy weights--shapedown BC: a family-centered, multidisciplinary program that reduces weight gain in obese children over the short-term. Int J Environ Res Public Health (2011) 0.82
The role of pharmacotherapy in the management of self-regulation difficulties in young children. J Can Acad Child Adolesc Psychiatry (2009) 0.82
Therapeutic drug levels of second generation antipsychotics in youth: a systematic review. J Child Adolesc Psychopharmacol (2015) 0.79
A review of escitalopram and citalopram in child and adolescent depression. J Can Acad Child Adolesc Psychiatry (2011) 0.79
Controversies in childhood bipolar disorders. Can J Psychiatry (2007) 0.78
Metabolic monitoring training program implementation in the community setting was associated with improved monitoring in second-generation antipsychotic-treated children. Can J Psychiatry (2012) 0.77
Quetiapine treatment in youth is associated with decreased insulin secretion. J Clin Psychopharmacol (2014) 0.77
Do Hospital and Community SSRI Usage Patterns in Children and Adolescents Match the Evidence? J Can Acad Child Adolesc Psychiatry (2010) 0.77
[Not Available]. Paediatr Child Health (2012) 0.76
Review: evidence on the comparative effectiveness and adverse effects of antipsychotics in young people is limited. Evid Based Ment Health (2012) 0.75
Cognitive enhancers. CMAJ (2013) 0.75
A retrospective study of antipsychotic drug switching in a pediatric population. BMC Psychiatry (2013) 0.75
Atypical antipsychotics for psychosis in adolescents. Paediatr Child Health (2014) 0.75
Diagnosing concussion. CMAJ (2013) 0.75
Postconcussional symptoms not a syndrome. Psychosomatics (2006) 0.75
Health Information Preference among Youth and Caregivers related to Second-Generation Antipsychotic Treatment. J Can Acad Child Adolesc Psychiatry (2012) 0.75
Protecting academic freedom. Open Med (2008) 0.75
Competing interests of authors. CMAJ (2009) 0.75
Effectiveness of an educational handbook in improving psychiatry resident knowledge of second-generation antipsychotics. Acad Psychiatry (2014) 0.75